Xing Li

Title: Innovations of Xing Li in Immunomodulatory Medicine

Introduction

Xing Li is a prominent inventor based in Xi'an, China. He has made significant contributions to the field of immunomodulatory medicine, particularly through his research on ellagic acid and its applications. His work focuses on developing treatments for neuromyelitis optica and immune rejection following skin transplantation.

Latest Patents

Xing Li holds a patent for the "Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation." This patent outlines the use of ellagic acid and its metabolic derivative, urolithin, in creating an immunomodulatory medicine. The research employs classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis and neuromyelitis optica mouse models. The experiments demonstrate that ellagic acid and its derivatives significantly improve recovery from autoimmune conditions and inhibit inflammatory cell infiltration into the central nervous system. Additionally, they ameliorate the severity of experimental colitis, reduce brain damage, and enhance immune tolerance.

Career Highlights

Xing Li is affiliated with Shaanxi Normal University, where he conducts his research and develops innovative medical solutions. His work has garnered attention for its potential clinical applications and development prospects in treating autoimmune diseases.

Collaborations

Xing Li collaborates with notable colleagues, including Yuan Zhang and Wenhui Qi, who contribute to his research efforts and enhance the scope of his work.

Conclusion

Xing Li's innovative research on ellagic acid represents a significant advancement in immunomodulatory medicine. His contributions have the potential to improve treatment outcomes for patients suffering from autoimmune diseases and enhance the understanding of immune tolerance.